Actelion focuses on the discovery and development of innovative medicines to serve high unmet medical needs in areas such as cardiovascular, central nervous system, oncology and immunology, as well as anti-infective indications.
Actelion focuses on the discovery and development of innovative medicines to serve high unmet medical needs in areas such as cardiovascular, central nervous system, oncology and immunology, as well as anti-infective indications.
Pulmonary arterial hypertension (PAH) is a serious disease of the arteries connecting the lungs to the heart (the pulmonary arteries).
Systemic sclerosis (SSc) is a chronic disease where the immune system, which normally protects the body from infections and disease, starts to attack the body’s own cells, causing tissue destruction.
Type 1 Gaucher disease, an inherited autosomal recessive disorder, is the most common disease among all inherited glycosphingolipid storage disorders, affecting approximately 7,000 patients worldwide.
Niemann-Pick type C disease (NP-C) is a rare genetic disorder caused by accumulation of fatty molecules such as cholesterol, due to a defect in the movement of fatty molecules within the cells of the body, including the brain.
Actelion clinical trial activities
Actelion aims to bring innovative medicines to patients through its research, drug development and clinical trial activities.
